Fig. 8: The expression of PRMT5 is upregulated in multiple carcinomas and is a potential cancer biomarker.
From: Snail/PRMT5/NuRD complex contributes to DNA hypermethylation in cervical cancer by TET1 inhibition
A, B PRMT5 is upregulated in multiple carcinomas. Immunohistochemical staining of PRMT5 in paired samples of lung, esophagus, stomach, colon, liver, pancreas, cerebrum, kidney, prostate, skin, breast, ovary, uterine cervix, and lymphoma versus adjacent normal tissue. Representative images of 200-fold magnification of each type of paired tumor section are presented. C PRMT5 expression in multiple cancer microarray datasets available from Oncomine (https://www.oncomine.com/). D Kaplan–Meier survival analysis of the relationship between survival time and PRMT5 signature in breast, lung, liver, and gastric cancer using the online tool. E Analysis of published clinical datasets (GSE50811, GSE66294, and GSE38832) for the expression of TET1, E-cadherin, and expression of PRMT5 by two-tailed unpaired t-test (*p < 0.05, **p < 0.01, ***p < 0.001). F Graphic model as discussed in the text. DNA (black line); unmethylated CpG sites (hollow circle); methylated CpG sites (blue circle); H4R3me2s and H3R8me2s (orange ball); pan-acetylated H3 (green flag).
